Yoon Minki, Jung Soo Jin, Kim Tae Hyun, Ha Tae Kwun, Urm Sang-Hwa, Park Ji Sun, Lee Seok Mo, Bae Sang Kyun
a Department of Nuclear Medicine , Good Samaritan Hospital , Pohang , Korea .
b Department of Pathology .
Endocr Res. 2016;41(1):64-9. doi: 10.3109/07435800.2015.1066803. Epub 2015 Oct 29.
The purpose of this study was to evaluate the expression of the glucose transporters GLUT1 and GLUT3 in papillary thyroid carcinomas (PTCs) and to elucidate their relationship with the BRAF V600E mutation and F-18 FDG uptake.
We retrospectively analyzed data of 52 PTC patients (41 women and 11 men; mean age, 52.4 ± 14.5 years). F-18 FDG PET/CT was performed preoperatively, and the maximum standardized uptake value (SUVmax) was calculated. GLUT1/GLUT3 expression was determined immunohistochemically, and the BRAF V600E mutation was detected using DNA sequencing.
GLUT1 and GLUT3 were expressed in 82.7% (43/52) and 59.6% (31/52) PTCs, respectively. The BRAF V600E mutation was detected in 65.4% (34/52) PTCs. The odds ratio between GLUT1 expression and the BRAF V600E mutation was 5.2 (95% CI, 1.11-24.05; p < 0.05), and that between GLUT3 expression and the BRAF V600E mutation was 3.8 (95% CI, 1.14-12.53; p < 0.05). The SUVmax of PTCs was significantly higher if they carried the BRAF V600E mutation (11.3 ± 2.0, compared with 5.7 ± 1.4 for wild type BRAF tumors, Mann-Whitney test, p = 0.016). Neither GLUT1 nor GLUT3 expression was significantly associated with the SUVmax of F-18 FDG PET/CT in PTCs.
Our findings confirmed that both GLUT1 and GLUT3 are strongly expressed by PTCs, although their expression was not significantly associated with the SUVmax of F-18 FDG PET/CT. However, GLUT1 and GLUT3 expressions were significantly associated with the presence of the BRAF V600E mutation, and the SUVmax of tumors was significantly higher in the presence of the mutated BRAF gene.
本研究旨在评估葡萄糖转运蛋白GLUT1和GLUT3在甲状腺乳头状癌（PTC）中的表达，并阐明它们与BRAF V600E突变及F-18 FDG摄取的关系。
我们回顾性分析了52例PTC患者（41例女性和11例男性；平均年龄52.4±14.5岁）的数据。术前进行F-18 FDG PET/CT检查，并计算最大标准化摄取值（SUVmax）。采用免疫组织化学方法测定GLUT1/GLUT3表达，使用DNA测序检测BRAF V600E突变。
GLUT1和GLUT3分别在82.7%（43/52）和59.6%（31/52）的PTC中表达。65.4%（34/52）的PTC检测到BRAF V600E突变。GLUT1表达与BRAF V600E突变之间的优势比为5.2（95%CI，1.11 - 24.05；p<0.05），GLUT3表达与BRAF V600E突变之间的优势比为3.8（95%CI，1.14 - 12.53；p<0.05）。携带BRAF V600E突变的PTC的SUVmax显著更高（11.3±2.0，野生型BRAF肿瘤为5.7±1.4，曼-惠特尼检验，p = 0.016）。GLUT1和GLUT3的表达均与PTC中F-18 FDG PET/CT的SUVmax无显著相关性。
我们的研究结果证实，PTC中GLUT1和GLUT3均强烈表达，尽管它们的表达与F-18 FDG PET/CT的SUVmax无显著相关性。然而，GLUT1和GLUT3的表达与BRAF V600E突变的存在显著相关，且存在BRAF基因突变时肿瘤的SUVmax显著更高。
